BTG reiterates full-year guidance

29th Jan 2014 07:38

- Underlines full-year revenue guidance- Trading year-to-date in with expectations- Full-year revenue range of 275m to 285m poundsFTSE-250 healthcare company BTG said trading for the four months to January 28th has been in line with expectations as it reiterated full-year revenue guidance.The group, which develops products targeting critical care, cancer and other disorders, said it remains confident of achieving revenue between £275m to £285m for the financial year ending March 31st 2014. Chief Executive Louise Makin said: "BTG has made strong progress in 2013. The acquisitions of TheraSphere and EKOS Corporation, together with the recent approval of Varithena, give us the platform to become a commercial and scientific leader in Interventional Medicine. "With the continued strong financial underpin from our Specialty Pharmaceuticals and Licensing segments, we will continue to execute our commercial and development plans to deliver sustainable and profitable long-term growth."CJ